Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13590027 | 0.86 | S100B (0.50) | KMT2AALDH1A1S100BMAPTSMN1; SMN2 | |
| SCHEMBL242948 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAOAS100BPTGS2 | |
| SCHEMBL242949 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAOAS100BPTGS2 | |
| SCHEMBL13754812 | 0.83 | S100B (0.52) | KMT2AALDH1A1MAOAS100BPTGS2 | |
| SCHEMBL13590019 | 0.82 | ALDH1A1 (0.37) | KMT2AALDH1A1S100BMAPTMEN1 | |
| SCHEMBL4865610 | 0.80 | S100B (0.50) | KMT2AALDH1A1MAOAS100BPTGS2 | |
| SCHEMBL5676571 | 0.80 | S100B (0.50) | KMT2AALDH1A1MAOAS100BPTGS2 | |
| SCHEMBL7091916 | 0.75 | ALDH1A1 (0.48) | KMT2AALDH1A1S100BPTGS2PTGS1 | |
| SCHEMBL85152 | 0.75 | MAPT (0.47) | KMT2AALDH1A1S100BCYP2A6MAPT | |
| SCHEMBL23367976 | 0.74 | KMT2A (0.44) | KMT2AALDH1A1MAOAS100BPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2018-05-24 | — | — | US | disclosed |
| US-9724346-B2 | Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | AFFERENT PHARMACEUTICALS INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | AFFERENT PHARMACEUTICALS INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20160271131-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160263112-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | Afferent Pharmaceuticals, Inc. (US) | 2016-09-15 | — | — | US | disclosed |
| US-9102665-B2 | Cysteinyl leukotriene antagonists | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-11 | — | — | US | disclosed |
| US-8846705-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-06-05 | — | — | US | disclosed |
| WO-2014080615-A1 | RECORDING MATERIAL PRODUCED USING NON-PHENOL COMPOUND | 日本曹達株式会社 (JP) | 2014-05-30 | — | — | WO | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC | 2011-03-31 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| WO-2003084662-A2 | COVALENTLY FIXED LIGAND SYSTEMS, NON-METALLOCENE SYSTEMS AND CATALYST SYSTEMS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR POLYMERIZING OLEFINS | CELANESE VENTURES GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | KMT2A 996/4885ALDH1A1 748/4885MAOA 991/4885 |
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885ALDH1A1 2017/4885MAOA 2135/4885 |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | P2RX3, P2RX2, P2RX5 | KMT2A 1567/4885ALDH1A1 1472/4885MAOA 2046/4885 |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3712/4885ALDH1A1 2077/4885MAOA 2752/4885 |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | TYMP, RPL35, EIF2AK2 | KMT2A 3231/4885ALDH1A1 1660/4885MAOA 1381/4885 |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | KMT2A 3706/4885ALDH1A1 2017/4885MAOA 2135/4885 |
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | LTC4S, CYSLTR2, CYSLTR1 | KMT2A 3738/4885ALDH1A1 2177/4885MAOA 2129/4885 |
| US-20160271131-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | KMT2A 3752/4885ALDH1A1 2230/4885MAOA 2995/4885 |
| US-20160263112-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | P2RX3, P2RX2, P2RX1 | KMT2A 3539/4885ALDH1A1 1128/4885MAOA 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.